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A cute kidney injury (AKI) after cardiovascular surgery is common [1],  particularly after aortic 
surgery.  However,  there is wide variation in the 
reported incidence of AKI following aortic surgery due 
to the existence of different definitions of AKI and con-
founding patient factors [2].  Total arch replacement 
(TAR) is one of the most complex and challenging pro-
cedures for cardiovascular surgeons where many 
patients develop AKI afterwards.  A recent study sug-
gests that advanced age,  elevated body mass index 
(BMI),  elevated preoperative serum creatinine (sCr),  
and prolonged cardiopulmonary bypass (CPB) time are 
independent risk factors for AKI following aortic arch 
surgery [3].  However,  the risk factors for AKI follow-
ing TAR are not fully understood.  Moreover,  the defi-
nition of AKI differs greatly among studies,  and data on 
AKI defined using the Kidney Disease Improving 
Global Outcome (KDIGO) criteria are scarce [4].
Over the past decades,  TAR has been frequently 
performed under deep hypothermic circulatory arrest 
(DHCA) to provide a bloodless and still operative field,  
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Many patients develop acute kidney injury (AKI) after vascular surgery.  In this retrospective observational 
study,  we investigated the risk factors for AKI defined using the Kidney Disease Improving Global Outcomes 
criteria after total arch replacement (TAR).  Additionally,  we investigated the influence of temperature manage-
ment during cardiopulmonary bypass (CPB) on postoperative renal function by propensity score-matched anal-
ysis.  We retrospectively analyzed 161 consecutive patients who underwent TAR between 2016 and 2019.  
Postoperative AKI occurred in 48.7% of the patients.  In the multivariate analysis,  male sex (odds ratio [OR] 
3.95,  95% confidence interval [95%CI] 1.56-8.27,  p= 0.002),  ACE inhibitors/ARB medication (OR 3.19,  
95%CI 1.49-6.82,  p= 0.003),  preoperative chronic kidney disease (OR 2.47,  95%CI 1.17-5.23,  p= 0.02),  pro-
longed CPB time (OR 2.36,  95%CI 1.05-5.34,  p= 0.04),  and lower body ischemic time during CPB (OR 2.20,  
95%CI 1.05-4.46,  p= 0.04) were identified as independent risk factors for AKI.  Propensity score-matched anal-
ysis showed no significant difference in the risk of AKI following TAR between mild hypothermia or normo-
thermia and moderate hypothermia (37.2% vs. 41.9%,  p= 0.83).  In conclusion,  modifiable risk factors for AKI 
included prolonged CPB time and lower body ischemic time.  Temperature management during CPB had no 
clear effect on outcomes.
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but it is a time-consuming process,  and the potential 
side effect of coagulopathy is a great concern.  In the 
2010s,  a protocol of moderate hypothermic circulatory 
arrest (MHCA),  sometimes combined with selective 
antegrade cerebral perfusion (SCP),  was widely 
accepted as a preferred alternative to DHCA since 
acceptably low rates of adverse neurological and renal 
events were reported using this modality [5].  
Nonetheless,  a few surgeons tried to push the limit by 
using mild rather than moderate hypothermia for TAR.  
Therefore,  the debate about the optimal temperature for 
TAR remains unsettled.
Newland et al.  reported that hyperthermic perfusion 
during CPB is an independent predictor of AKI follow-
ing cardiac surgery [6].  In general,  higher temperature 
is thought to risk harm to various organs including the 
brain and kidneys.  On the other hand,  previous studies 
suggest that MHCA with antegrade selective cerebral 
perfusion during complex aortic surgery is not associ-
ated with an increased risk of AKI [7].  At our institu-
tion,  for example,  the target temperature during CPB is 
often higher than 28°C,  which establishes a condition 
called mild hypothermic circulatory arrest,  and if the 
open distal anastomosis is unnecessary and the surgeon 
speculates that a neurological complication is unlikely 
to happen,  normothermic (> 34°C) circulatory arrest 
with SCP is sometimes performed.  However,  little is 
known about the influence of mild hypothermic or nor-
mothermic circulatory arrest on postoperative renal 
function or patient outcome.
This study aimed to investigate the clinical risk fac-
tors for AKI,  as defined using the KDIGO criteria,  fol-
lowing TAR,  one of the most performed procedures in 
vascular surgery.  In addition,  we focused on the influ-
ence of temperature management during CPB on post-
operative renal function by comparing the effects of 
mild hypothermia/normothermia to those of conven-
tional MHCA.
Materials and Methods
Study design. This study was a retrospective 
analysis of a prospectively collected cohort.  After insti-
tutional review board approval (approval number,  
2019-126),  we reviewed the electronic medical records 
and laboratory results of 161 consecutive patients who 
underwent TAR surgery with CPB at Hiroshima City 
Hospital,  Japan,  between January 2016 and March 
2019.  Patients who underwent both elective and emer-
gent TAR were enrolled,  in the study and those with 
chronic kidney disease who needed renal replacement 
therapy before surgery were excluded.  The need for 
informed consent was waived because of the retrospec-
tive nature of the study.
In the first analysis,  we investigated the risk factors 
for AKI following TAR,  and in the second analysis,  we 
compared the effect of temperature management on 
AKI following TAR.
Data collection. We retrospectively reviewed the 
clinical records and data on patient demographics,  
details of medical and surgical treatments and postop-
erative patient outcomes.  Demographic variables 
included age,  sex,  BMI,  underlying disease,  comor-
bidities (diabetes,  hypertension,  pulmonary disease,  
coronary artery disease,  cerebrovascular disease,  
chronic kidney disease and heart failure),  medication 
history (angiotensin converting enzyme inhibitors 
[ACE inhibitors],  angiotensin-II receptor blockers 
[ARBs],  calcium channel blockers,  β-blockers,  and 
statins).
Preoperative laboratory variables included sCr,  esti-
mated glomerular filtration rate (eGFR),  hemoglobin,  
and albumin levels.  Preoperative hemodynamic infor-
mation included left ventricular ejection fraction (via 
the modified Simpson method),  and pulmonary hyper-
tension detected by echocardiography.  The eGFR rate 
was derived from the Modification of Diet in Renal 
Disease Equation: eGFR (mL/min/1.73 m2) = 194 ×  
[sCr (mg/dL)]−1.094 × [age (years)]−0.287 ( × 0.739 if 
female) [8].
Postoperative laboratory variables included hemo-
globin at intensive care unit (ICU) admission,  and 
maximum sCr within 7 days after surgery.  Surgical 
details inrolved previous cardiac surgery,  emergent or 
elective status,  and type of combined surgery (Bentall 
procedure,  coronary artery bypass grafting [CABG],  
and aortic valve replacement/plasty).
Operation-related variables were the durations of 
operation,  CPB,  and aortic cross-clamping,  the lower 
body ischemic time,  and the minimum core tempera-
ture during CPB.  In addition,  we analyzed the amount 
of blood products and the continuously administered 
drugs used (dobutamine,  milrinone,  norepinephrine,  
epinephrine,  carperitide,  landiorol,  and nicardipine).
The outcome measures were postoperative variables 
including hemoglobin at ICU admission,  and postop-
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erative sCr for 7 consecutive days.  Finally,  patients’ 
outcomes (ICU length of stay,  intubation time,  reintu-
bation,  severe infection,  neurological complications,  
and redo operation) were also analyzed.
In the second analysis,  patients were divided into 2 
groups: a moderate hypothermia (MHCA) group,  and 
a mild hypothermia/normothermia (non-MHCA) 
group.  We investigated the effect of temperature man-
agement on AKI following TAR using propensity score 
(PS) matching.
Definitions. Preoperative chronic kidney disease 
(CKD) was defined as eGFR < 60 mL/min/1.73 m2.  
AKI was defined and staged for severity using the 
KDIGO criteria.  Postoperative AKI was defined as an 
increase in sCr to more than 50% of the baseline within 
7 days postoperatively or an increase of 0.3 mg/dL 
within 48 h postoperatively.  In this study,  we did not 
use urine output data because there are many con-
founding factors,  such as diuretics,  and the retrospec-
tively collected data may have the potential to be inac-
curate.  Regarding temperature management during 
CPB,  deep hypothermia was defined as a minimum 
core temperature below 20°C,  moderate hypothermia 
was defined as a minimum core temperature between 
20.1°C and 28°C,  mild hypothermia was defined as a 
core temperature between 28.1°C and 34°C,  and nor-
mothermia was defined as a core temperature between 
34.1°C and 36°C [9].
Major adverse complications consisted of stroke,  
paraplegia,  severe heart failure requiring mechanical 
support,  redo surgery,  the need for renal replacement 
therapy,  and sepsis.
Statistical analysis. All statistics are presented as 
the mean ± standard deviation (SD) or median (inter-
quartile range; IQR) for continuous variables as appro-
priate,  and as numbers and percentages for categorical 
variables.  The Mann-Whitney U test was used to com-
pare continuous variables,  and the χ2 or Fisher’s exact 
test was used to compare categorical variables.  A logis-
tic regression model was used to identify multivariate 
predictors of AKI.  For all analyses,  a p-value less than 
0.05 was considered to be statistically significant.  All 
data were analyzed using EZR version 3.4.1. (Saitama 
Medical Center,  Jichi Medical University,  Japan),  which 
is a graphical user interface for R (The R Foundation for 
Statistical Computing,  Vienna,  Austria),  a modified 
version of R commander designed to add statistical 
functions frequently used in biostatistics [10].
Results
Patient characteristics. In this retrospective 
cohort study,  158 patients were included after the 
exclusion of 3 patients with end-stage renal failure 
before surgery.  As shown in Table 1,  the median age 
was 69 ± 11.2 years (range: 22-88 years),  and 107 
(67.7%) of these patients were men.  Among the 158 
patients included,  122 patients (77.2%) were diagnosed 
with hypertension.  Other comorbidities included dia-
betes (n = 24,  15.1%),  pulmonary disease (n = 6,  3.7%),  
coronary artery disease (n = 32,  20.2%),  and cerebro-
vascular disease (n = 18,  11.3%).  All patients were 
hemodynamically stable before surgery,  and preopera-
tive echocardiography showed pulmonary hypertension 
in 8 (5.0%) patients,  and apparent valvular disease in 
26 (16.4%) patients.  Preoperative laboratory data showed 
the mean sCr level was 0.95 ± 0.41 mg/dL,  and the mean 
eGFR level was 62.0 ± 19.0 mL/min.  Regarding surgical 
details,  25 (15.8%) surgeries were emergent,  and com-
bined surgery was as follows: Bentall procedure 
(n = 11,  6.9%),  CABG (n = 12,  7.5%),  and aortic valve 
replacement/plasty (n = 17,  10.7%).  The mean opera-
tion time was 414.6 ± 97.4 min,  and the mean CPB time 
was 183.0 ± 57.8 min.  During CPB,  the mean lower 
body ischemic time was 22.6 ± 16.1 min,  and the mean 
minimum core temperature was 27.7 ± 2.4°C.
Analysis of risk factors for postoperative AKI. As 
shown in Table 1,  the group of patients with AKI was 
significantly different from those without AKI with 
respect to each of the following: sex,  BMI,  coronary 
artery disease,  CKD,  ACE inhibitors/ARB medication,  
preoperative sCr,  and eGFR.  There were significant 
differences between the two groups in operation time 
and lower body ischemic time during CPB.  The mini-
mum core temperature was not significantly different 
between the 2 groups.  Moreover,  the amount of intra-
operative blood product use and perioperative drug use 
were not significantly different.
The overall incidence of postoperative AKI defined 
using the KDIGO criteria was 48.7% (n = 77): 87% 
(n = 67) of these patients were classified as having stage 
1,  7.7% (n = 6) as having stage 2,  and 5.1% (n = 4) as 
having stage 3 AKI.  Table 2 shows the outcome data of 
the patients who underwent TAR replacement.  
Postoperative AKI was associated with prolonged ICU 
stay,  prolonged intubation time,  and reintubation rate.
We selected candidate variables for multivariate 
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Table 1　 Patients characteristics
All patients No AKI AKI P-value＊
Patients Population (n) 158 81 77
Demographic data
　Age (year),  mean ± SD 66.9±11.2 68.8±11.8 69.8±10.7 0.56
　Sex,  male (n) 107 (67.7%) 44 (54.3%) 63 (81.8%) 0.0003
　Body mass index (kg/m2),  mean±SD 23.6±3.6 22.9±3.4 24.3±3.7 0.018
Comorbidities
　Diabetes (n) 24 (15.1%) 9 (11.1%) 15 (19.4%) 0.21
　Hypertension (n) 122 (77.2%) 60 (74%) 62 (80.5%) 0.44
　Pulmonary disease (n) 6 (3.7%) 5 (6.1%) 1 (1.2%) 0.23
　Coronary artery disease (n) 32 (20.2%) 10 (12.3%) 22 (28.5%) 0.019
　Cerebrovascular disease (n) 18 (11.3%) 8 (9.8%) 10 (12.9%) 0.71
　Chronic kidney disease (n) 81 (51.2%) 32 (39.5%) 49 (63.6%) 0.003
　Heart failure (n) 21 (13.2%) 10 (12.3%) 11 (14.3%) 0.81
Preoperative medications
　ACE inhibitors/ARB medication (n) 63 (39.8%) 22 (27.1%) 41(53.2%) 0.014
　Calcium blocker (n) 24 (15.1%) 9 (11.1%) 15 (19.4%) 0.051
　β blocker (n) 38 (24.0%) 18 (22.2%) 20 (25.9%) 0.71
　Statin (n) 47 (29.7%) 18 (22.2%) 29 (37.6%) 0.051
Preoperative laboratory data
　Serum creatinine (mg/dL) 0.95±0.41 0.83±0.22 1.08±0.52 0.0001
　eGFR (mL/min/1.73 m2) 62.0±19.0 67.2±18.8 56.6±17.7 0.0003
　Hemoglobin (g/dL) 13.0±1.6 13.0±1.4 13.0±1.7 0.94
　Albumin (g/dL) 3.9±0.4 4.0±0.3 3.9±0.4 0.2
Preoperative hemodynamics
　Left ventricular ejection fraction (%),  mean±SD 65.7±6.7 66.5±6.0 64.9±7.2 0.13
　Pulmonary hypertension (n) 8 (5%) 4 (4.9%) 4 (5.1%) 1
　Valvular disease (n) 26 (16.4%) 12 (14.8%) 14 (18.1%) 0.72
Surgical details
　Emergent operation (n) 25 (15.8%) 11 (13.5%) 14 (18.1%) 0.56
　Previous cardiac surgery (n) 6 (3.7%) 3 (3.7%) 3 (3.8%) 1
　Combined surgery (n) 45 (28.4%) 22 (27.1%) 23 (298%) 0.8
　　Bentall procedure (n) 11 (6.9%) 7 (8.6%) 4 (5.1%) 0.53
　　Coronary artery bypass grafting (n) 12 (7.5%) 2 (2.4%) 10 (12.9%) 0.015
　　Aortic valve replacement/plasty (n) 17 (10.7%) 10 (12.3%) 7 (9.0%) 0.61
　Operation time (min),  mean±SD 414.6±97.4 396.1±79.0 434.0±110.8 0.014
　Cardiopulmonary bypass duration (min) 183.0±57.8 174.5±44.1 191.9±68.4 0.059
　Aortic cross-clamp time (min) 119.2±44.8 114.0±37.7 124.0±51.0 0.18
　Lower body ischemic time (min) 22.6±16.1 18.9±16.6 26.4±14.6 0.003
　Minimum core temperature (°C) 27.7±2.4 27.9±2.4 27.3±2.2 0.07
Intraoperative blood product use (unit)
　Red blood cell (u) 6.1±4.0 6.4±4.0 5.7±4.0 0.31
　Fresh frozen plasma (u) 9.2±3.8 8.6±3.5 9.7±3.8 0.067
　Platelets (u) 16.5±6.4 16.0±7.0 16.8±5.6 0.41
Perioperative drug use
　Dobutamine(n) 10 (6.3%) 3 (3.7%) 7 (9.0%) 0.28
　Milrinone(n) 4 (2.5%) 2 (2.4%) 2 (2.5%) 1
　Norepinephrine(n) 27 (17%) 14 (17.2%) 13 (16.8%) 1
　Epinephrine(n) 2 (1.2%) 0 (0%) 2 (2.5%) 0.45
　Carperitide(n) 65 (41.1%) 35 (43.2%) 30 (38.9%) 0.70
　Landiorol(n) 48 (30.3%) 19 (23.4%) 29 (37.6%) 0.07
　Nicardipine(n) 32 (20.2%) 13 (16.0%) 19 (24.6%) 0.25
AKI,  acute kidney injury; SD,  standard deviation.
＊Comparing patients without AKI to patients with AKI.
analysis of risk factors for AKI defined using the 
KDIGO criteria from previous reports and univariate 
analysis in this study [11].  The confounding factors 
included sex,  BMI,  use of ACE inhibitors/ARBs,  pre-
operative CKD,  coronary artery disease,  CPB time,  
and lower body ischemic time.  Table 3 shows the 
results of multivariate analysis of the risk factors.  Male 
sex (odds ratio [OR] 3.95,  95% confidence interval 
[95%CI] 1.56-8.27,  p = 0.002),  ACE inhibitors/ARBs 
(OR 3.19,  95%CI 1.49-6.82,  p = 0.003),  preoperative 
CKD (OR 2.47,  95%CI 1.17-5.23,  p = 0.02),  prolonged 
CPB duration (OR 2.36,  95%CI 1.05-5.34,  p = 0.04),  
and prolonged lower body ischemic time during CPB 
(OR 2.2,  95%CI 1.05-4.6,  p = 0.04) were identified as 
independent risk factors for AKI following TAR.
MHCA compared to normothermic or mild hypo-
thermic circulatory arrest. Among all patients 
enrolled in this study,  a total of 115 patients experi-
enced MHCA,  whereas 43 patients experienced non-
MHCA.  The propensity score (PS)  model incorporated 
seven variables,  i.e.,  sex,  age,  BMI,  ACE inhibitors/
ARBs,  cerebral disease,  left ventricular ejection frac-
tion,  and preoperative creatinine clearance (CCR).  The 
PS model was conducted using multivariate logistic 
regression,  in which the probability of receiving non-
MHCA was estimated for each patient.  Table 4 shows 
the results of the multivariate logistic regression model 
for receiving non-MHCA.  Finally,  the MHCA cases 
were matched to non-MHCA cases using the nearest 
neighbor algorithm method.
A total of 43 matched pairs were obtained using 
8 significant variables.  As shown in Table 5,  patients 
with MHCA showed a trend toward a significantly 
lower rate of female sex (MHCA 26.1% vs. non-MHCA 
48.8%,  p = 0.0008),  BMI (MHCA 24.2 ± 3.6 vs. non-
MHCA 22.3 ± 3.3,  p = 0.003),  and preoperative creati-
nine clearance (MHCA 59.8 ± 11.2 mL/min vs. non-
MHCA 68.1 ± 20.0 mL/min,  p = 0.015).  After PS 
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Table 2　 Outcome data
All patients No AKI AKI P-value＊
Patients Population (n) 158 81 77
Outcomes
ICU length of stay (days),  median± IQR 5.0 [4.0,  7.0] 5.0 [3.0,  6.0] 5.0 [4.0,  7.0] <0.001
Intubation time (hours),  median± IQR 14 [6.0,  20.7] 12 [6.0,  17.0] 15.0 [8.0,  42.0] 0.012
Major complication (n) 14 (8.8%) 5 (6.1%) 9 (11.6%) 0.34
　Neurological complication (n) 6 (3.7%) 3 (3.7%) 3 (3.8%) 1
　Renal replacement therapy (n) 1 (0.6%) 0 (0%) 1 (1.2%) 0.48
　Infection (n) 2 (1.2%) 0 (0%) 2 (2.5%) 0.24
　Redo surgery (n) 3 (1.8%) 2 (2.4%) 1 (1.2%) 1
　Reintubation (n) 5 (3.1%) 0 (0%) 5 (6.4%) 0.025
90-day mortality (n) 1 (0.6%) 0 (0%) 1 (1.2%) 0.48
AKI,  acute kidney injury; ICU,  intensive care unit; IQR,  interquartile range.
＊Comparing patients without AKI to patients with AKI.
Table 3　 Multivariate analysis of risk factors for AKI following TAR
Variables Odds ratio 95% Confidence interval P-value
Sex male 3.95 1.56-8.27 0.002
BMI 1.04 0.94-1.16 0.45
ACE-Ⅰ/ARB 3.19 1.49-6.82 0.003
CKD 2.47 1.17-5.23 0.02
Coronary artery disease 1.82 0.74-4.51 0.19
CPB time >180 min 2.36 1.05-5.34 0.04
Lower body ischemic time >25 min 2.20 1.05-4.46 0.04
BMI,  body mass index; ACE-Ⅰ,  angiotensin converting enzyme inhibitor; ARB,  angiotensin-Ⅱ receptor blocker; CKD,  chronic kidney dis-
ease; CPB,  cardiopulmonary bypass.
matching,  the significance of these differences disap-
peared (Table 5),  and the lower body ischemic time was 
significantly different between the 2 groups (MHCA 
23.0±14.0 min vs. non-MHCA 13.6±17.4 min,  p=0.007).  
Table 6 shows the major outcome measures after PS 
matching,  and the results showed that AKI was not 
significantly different between the 2 groups (MHCA 
41.9% vs. non-MHCA 37.2%,  p = 0.83).
Discussion
In this retrospective observational study,  the inci-
dence of postoperative AKI defined using the KDIGO 
criteria following TAR was 48.7%.  In the first analysis,  
we found that male sex,  ACE inhibitors/ARBs,  preop-
erative CKD,  prolonged CPB time,  and prolonged 
lower body ischemic time were independent risk factors 
for AKI following TAR.  In the second analysis,  i.e.,  the 
investigation of temperature management during CPB,  
our study indicated that,  compared with moderate 
hypothermia circulatory arrest,  mild hypothermia and 
normothermia circulatory arrest were weakly associ-
ated with worsening renal function after TAR.
The incidence of postoperative AKI in our study was 
relatively high at 48.7%.  The incidence of AKI after 
aortic surgery ranges from 18% to 53% [12].  In recent 
years,  the definition of AKI has become more sensitive,  
since early detection of AKI is important.  The RIFLE 
criteria and the Acute Kidney Injury Network (AKIN) 
criteria have been used to monitor the severity and pro-
gression of AKI [13 , 14].  In 2012 the KDIGO criteria 
emerged as a more sensitive diagnostic tool for detect-
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Table 4　 Multivariate analysis of receiving non-MHCA for propensity score analysis
Variables Odds ratio 95% Confidence interval P-value
Sex female 2.03 0.92-4.48 0.48
Age 0.98 0.95-1.02 0.48
BMI＊ 0.87 0.76-0.98 0.03
ACE-Ⅰ/ARB medication 0.98 0.44-2.19 0.96
Cerebral disease 1.00 0.29-3.45 0.99
Ejection Fraction＊ 0.98 0.93-1.04 0.57
Preoperative CCR＊ 1.01 0.99-1.03 0.26
＊Odds ratio for increase of BMI of one kg/m2,  one percent of Ejection Fraction,  and one ml/min /1.73 m2 of CCR,  respectively.
BMI,  body mass index; ACE-Ⅰ,  angiotensin converting enzyme inhibitor; ARB,  angiotensin-Ⅱ receptor blocker; CCR,  creatinine clear-
ance.
Table 5　 Major results of Propensity-matched data
Variables









Sex,  female (n) 30 (26.1%) 21 (48.8%) 0.0008 16 (37.2%) 21 (48.8%) 0.83
Age (year),  mean±SD 69.8±11.1 68.1±11.7 0.419 69.2±12.1 68.1±11.7 0.67
Body mass index (kg/m2),  mean±SD 24.2±3.6 22.3±3.3 0.003 22.7±3.1 22.3±3.3 0.49
ACE inhibitors/ARB medication (n) 48 (41.7%) 15 (34.9%) 0.47 18 (41.9%) 15 (34.9%) 0.51
Preoperative CCR (ml/min/1.73 m2) 59.8±11.2 68.1±20.0 0.015 68.4±21.1 68.1±20.0 0.72
Chronic kidney disease (n) 64 (55.7%) 17 (39.5%) 0.077 20 (46.5%) 17 (39.5%) 0.66
Cerebrovascular disease (n) 14 (12.2%) 4 (9.3%) 0.781 7 (16.3%) 4 (9.3%) 0.52
Coronary artery disease (n) 26 (22.6%) 6 (14%) 0.272 9 (20.9%) 6 (14%) 0.57
Left ventricular ejection fraction (%) 65.8±6.8 65.7±6.7 0.944 66.4±5.9 65.7±6.7 0.61
Emergency operation (n) 18 (15.7%) 7 (16.3%) 1 4 (9.3%) 7 (16.3%) 0.52
MHCA,  moderate hypothermia circulatory arrest; SD,  standard deviation; ACE inhibitors,  angiotensin converting enzyme inhibitors; ARB,  
angiotensin-Ⅱ receptor blocker; CCR,  creatinine clearance; CPB,  cardiopulmonary bypass.
ing AKI.  The strict definition of the KDIGO criteria 
may have been responsible for the high incidence of 
AKI in our study.  On the other hand,  the mortality rate 
and rate of major complications were lower in our study 
compared to previous reports [11].  As a result,  we 
found that AKI following TAR was associated with pro-
longed ICU stay,  and with the reintubation rate,  but 
AKI was not associated with hard outcomes such as 
90-day mortality,  which is not consistent with the pre-
vious reports [15].  One possible explanation is that the 
mortality rate in this study was much lower than the 
average rate reported previously,  and the difference was 
not statistically significant.  However,  patients with AKI 
experienced longer ICU stays in this study.  These find-
ings reinforce the notion that AKI has a significant 
impact on patient outcome,  as well as a substantial 
impact in terms of medical costs and resources.
In our study,  ACE inhibitors/ARBs were identified 
as risk factors for postoperative AKI.  There is a lot of 
evidence of the benefits of ACE inhibitors/ARBs for the 
treatment of hypertension,  heart failure,  ischemic heart 
disease and proteinuric CKD.  However,  ACE inhibi-
tors/ARBs are considered to be associated with AKI in 
various settings [16 ,17],  particularly during acute 
hypovolemic illness.  Therefore,  patients with CKD 
should stop taking these agents if they become acutely ill 
[18].  The perioperative period is also clinically vulnera-
ble and vascular surgery is one of the most invasive pro-
cedures for patients.  Considering all the above,  it is 
reasonable to stop ACE inhibitors/ARBs before surgery.
It should also be noted that,  in this study,  none of 
the intravenously administered drugs were associated 
with AKI following TAR.  Numerous pharmacological 
agents including inotropes,  statins and erythropoietin 
have failed to demonstrate any benefit in terms of AKI 
prevention following cardiac surgery [19 , 20].  There are 
currently no drugs that can help prevent AKI after car-
diovascular surgery.  For this reason,  it might be 
important to focus not on the beneficial pharmacologi-
cal strategies but on the avoidance of potentially harm-
ful drugs,  such as non-steroidal anti-inflammatory 
drugs or ACE inhibitors/ARBs.
Additionally,  neither the amount of transfusion nor 
the perioperative hemoglobin level was a risk factor for 
postoperative AKI in this study.  These results may indi-
cate that the perioperative transfusion strategies should 
focus on oxygen delivery or the prevention of coagulop-
athy rather than AKI prevention.
In accordance with other studies,  our findings 
demonstrated that preexisting CKD is a strong predic-
tor for postoperative AKI,  and care should be taken 
when treating patients with CKD during the periopera-
tive period.
In this study,  the lower body ischemic time affected 
the incidence of impaired renal function.  Prolonged 
lower body ischemic time may cause postoperative AKI 
following TAR by promoting renal ischemia.  Since the 
lower body ischemic time is determined based on the 
complexity of the distal anastomosis,  prompt anasto-
mosis is needed to restore and improve the renal perfu-
sion.  Amano et al.  reported that lower body ischemic 
time is a risk factor for AKI following type A acute 
aortic dissection [21].  Similarly,  the prolonged CPB 
time was associated with worsening renal function in 
this study.  Importantly,  the lower body ischemic time 
and CPB time are both modifiable risk factors,  suggest-
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Table 6　 Major outcomes of Propensity-matched data
Variables










　Operation time (min),  mean±SD 416.5±102.4 409.5±83.6 0.689 402.6±76.3 409.5±83.6 0.69
　CPB time (min),  mean±SD 185±61.3 177.7±47.3 0.477 175.9±40.0 177.7±47.3 0.85
　Aorta clamp time (min),  mean±SD 118.6±46.3 120.9±41.2 0.767 110.9±33.7 120.9±41.2 0.22
　Lower body ischemic time (min),  mean±SD 26.2±14.2 13.6±17.4 0.001 23.0±14.0 13.6±17.4 0.007
Major complication (n)
　Acute kidney injury (n) 61 (53%) 16 (37.2%) 0.107 18 (41.9%) 16 (37.2%) 0.83
　Neurological complication (n) 5 (4.3%) 1 (2.3%) 1 2 (4.7%) 1 (2.3%) 0.85
CPB,  cardiopulmonary bypass; MHCA,  moderate hypothermia circulatory arrest.
ing the need to focus more precisely on these time-re-
lated parameters.
In the second analysis,  in which temperature man-
agement during CPB was investigated,  our results indi-
cated that neither mild hypothermia nor normothermia 
circulatory arrest was associated with worsening of renal 
function after TAR compared to moderate hypothermia 
circulatory arrest.  Historically,  deep hypothermic tem-
perature has been reported to be associated with coagu-
lopathy,  increased systemic inflammatory response,  
and increased risk of organ dysfunction.  In response to 
this,  several institutions have implemented warmer 
temperatures for aortic surgery.  Our own institution 
also adopted normothermia or mild hypothermia cir-
culatory arrest as a standard technique.  Importantly,  
surgeons tend to adopt higher temperature manage-
ment for their patients with normal cardiac function 
and no apparent preoperative neurological complica-
tions or CKD.  The contributors to PS matching were 
determined based on these factors.
However,  the ideal temperature for surgical repair of 
the aortic arch remains unclear.  Previous studies have 
shown similar results regarding temperature manage-
ment for postoperative AKI.  Tian et al.  reported that 
MHCA was not associated with a higher incidence of 
AKI than DHCA after aortic surgery for acute dissec-
tion [22].  Tsai et al.  concluded that MHCA is a safe and 
effective technique for organ protection in aortic sur-
gery with low mortality and morbidity [23].  
Meanwhile,  Fang reported that MHCA was not supe-
rior to DHCA in decreasing AKI following TAR in 
patients with type A aortic dissection [24].  These 
reports indicate that the incidence of AKI after vascular 
surgery is similar between DHCA and MHCA.  This 
study investigated the effect of the higher temperature 
management compared with MHCA on renal function 
following TAR.
Our data demonstrated that mild hypothermia/nor-
mothermia was not associated with AKI following TAR.  
Additionally,  the neurological outcomes were similar in 
both patients with and those without AKI.  Our data 
suggest that we can choose temperature management 
depending on the predisposing factors of the individual 
patient.  In general,  the organ-protective effect of lower 
temperature management during CPB is partly pro-
duced by reducing oxygen consumption,  but many 
factors during vascular surgery,  such as postoperative 
inflammatory response and coagulopathy,  may offset 
the organ protective effect.  It is reasonable to focus on 
the most vulnerable organ on a case-by-case basis.  In 
conclusion,  temperature management during CPB did 
not necessarily affect the patient outcomes in our study.
Our study has several limitations.  First,  this study 
was a single-center retrospective study,  and was not 
sufficiently powered to evaluate outcomes precisely.  
Because of its retrospective nature,  there may have been 
biases that were not accounted for in the results.  
Furthermore,  after PS matching,  each group had only 
43 patients in the second analysis,  which is below the 
necessary power for generalization.  Second,  the 
patients’ backgrounds,  especially the miscellaneous 
underlying diseases,  were not homogeneous.  In addi-
tim,  the TAR encompasses various surgical techniques,  
depending on accessibility,  emergency status,  and 
availability of cross-clamp sites.  More importantly,  
lower body ischemic time,  a modifiable risk factor in 
this study,  was dependent on the skill of the surgeon,  
hence our results do not necessarily apply to the strate-
gies at other facilities.  In addition,  we included 25 
emergency cases in this study.  All these patients were 
hemodynamically stable,  but their preoperative labora-
tory data,  including creatine levels,  were extracted in 
an emergency setting,  which may have caused some 
bias.  In addition,  CT contrast was used before all 
emergency cases,  which may have had an adverse effect 
on renal function,  although the univariate analysis 
revealed no statistically significant difference between 
patients undergoing emergent surgery and those who 
underwent elective surgery.  Third,  perioperative 
hemodynamic status was not considered in this study,  
that might have biased the results.  Finally,  lower body 
ischemic time was significantly lower in the non-
MHCA group than in the MHCA group in the matched 
analysis,  but the rate of postoperative AKI did not differ 
significantly between patients in the non-MHCA group 
and those in the MHCA group.  This finding is not con-
sistent with the multivariate analysis.  This discrepancy 
needs to be examined in further studies.
In summary,  we investigated the postoperative AKI 
following TAR using the KDIGO criteria.  Our data 
indicate that the independent risk factors for AKI fol-
lowing TAR include ACE inhibitors/ARBs,  male sex,  
preoperative CKD,  prolonged CPB duration,  and pro-
longed lower body ischemic time.  A mild hypother-
mia/normothermia strategy during CPB was not asso-
ciated with a higher incidence of AKI following TAR 
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compared to moderate hypothermia.  Future studies 
may explore the modifiable risk factors for postopera-
tive AKI such as lower body ischemic time and short-
ened CPB time.
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